Abstract
<sup>18</sup>F-T807 is a PET radiotracer developed for imaging tau protein aggregates, which are implicated in neurologic disorders including Alzheimer disease and traumatic brain injury (TBI). The current study characterizes <sup>18</sup>F-T807 pharmacokinetics in human subjects using dynamic PET imaging and metabolite-corrected arterial input functions. Nine subjects (4 controls, 3 with TBI history, 2 with mild cognitive impairment) underwent dynamic PET imaging for up to 120 min with arterial blood sampling. Total volume of distribution ($V_T$) was estimated using compartmental modeling and graphical analysis. Reference region-based methods, including Logan distribution volume ratio (DVR) and static SUV ratio (SUVR) using the cerebellum as a reference tissue, were explored. Results showed <sup>18</sup>F-T807 has properties suitable for tau quantification, with simplified approaches correlating highly ($R^2 = 0.97$) with gold-standard compartmental modeling.
Introduction
Tau protein aggregates are a hallmark of neurodegenerative diseases like Alzheimer’s and are also implicated in Traumatic Brain Injury (TBI). To study these diseases in living patients, researchers use Positron Emission Tomography (PET) with radiotracers that bind to tau. However, for a tracer to be clinically useful, its pharmacokinetics—how it enters the brain, metabolizes in the blood, and binds to its target—must be thoroughly understood. While the "gold standard" for quantification involves invasive arterial blood sampling, this study investigates whether <sup>18</sup>F-T807 can be reliably quantified using simpler, non-invasive imaging ratios.
Methods
The researchers performed 120-minute dynamic PET scans on 9 subjects (4 healthy controls, 3 with TBI, and 2 with Mild Cognitive Impairment [MCI]). Key technical approaches included:
- Arterial Input Function: Continuous arterial blood sampling and HPLC analysis were used to measure the concentration of the unmetabolized tracer in the plasma.
- Compartmental Modeling: They compared 1-tissue and 2-tissue models (1T, 2T, 2Tv) to determine the best fit for tracer kinetics.
- Graphical Analysis: Logan and Multilinear Analysis 1 (MA1) were used to estimate $V_T$.
- Reference Region Validation: The cerebellum was tested as a reference region to calculate DVR and SUVR, potentially eliminating the need for arterial lines.
Results and Discussion
Brain Kinetics and Penetration
<sup>18</sup>F-T807 showed high brain penetration, with gray matter uptake peaking quickly (SUV > 2 within ~5 minutes). The tracer demonstrated clear differentiation between clinical groups, with $V_T$ significantly higher in MCI subjects compared to controls in expected regions like the temporal and parietal cortices.
As shown in Figure 1, the cerebellum exhibited the lowest variability and fastest washout, confirming its suitability as a reference region for this tracer in the studied populations.
Validation of Simplified Quantification
The study's most significant finding was the extremely high correlation between complex, invasive modeling and simplified imaging metrics. The 2-tissue model with blood volume correction (2Tv) provided the best fit for the data, but simplified metrics like Logan DVR (at $t^* = 55$ min) and static SUVR (measured 80–100 minutes post-injection) were nearly identical in their results.
As illustrated in Figure 6, the correlation between the simplified SUVR$_{80-100}$ and the gold-standard 2Tv model reached an $R^2$ of 0.96 ($P < 0.0001$). This indicates that a 20-minute static scan can provide a highly accurate measurement of tau burden without the need for arterial sampling or 2-hour dynamic imaging.
Conclusion
This study provides the "green light" for using <sup>18</sup>F-T807 in clinical research using simplified protocols. While compartmental modeling remains the gold standard for initial tracer characterization, the high accuracy of the cerebellar reference tissue approach (specifically SUVR from 80–100 min) makes <sup>18</sup>F-T807 a practical and powerful tool for large-scale studies of tau pathology in Alzheimer disease and TBI.
Summary updated